Equities research analysts at Leerink Swann initiated coverage on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research note issued to investors on Tuesday. The firm set an “outperform” rating and a $180.00 price target on the specialty pharmaceutical company’s stock. Leerink Swann’s target price indicates a potential upside of 31.00% from the company’s current price.
Several other equities research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Wells Fargo & Co reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 25th. B. Riley reiterated a “buy” rating and issued a $206.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 20th. Cantor Fitzgerald reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Sunday, December 10th. Finally, Mizuho increased their price target on shares of Jazz Pharmaceuticals from $144.00 to $150.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 5th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $181.68.
Shares of Jazz Pharmaceuticals (JAZZ) traded up $2.75 during trading on Tuesday, hitting $137.40. 330,660 shares of the stock were exchanged, compared to its average volume of 406,645. Jazz Pharmaceuticals has a 12 month low of $106.85 and a 12 month high of $163.75. The stock has a market cap of $8,070.00, a PE ratio of 22.64, a price-to-earnings-growth ratio of 0.87 and a beta of 0.97. The company has a quick ratio of 2.94, a current ratio of 3.10 and a debt-to-equity ratio of 0.63.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Atlantic Trust Group LLC increased its position in Jazz Pharmaceuticals by 2.7% in the third quarter. Atlantic Trust Group LLC now owns 63,495 shares of the specialty pharmaceutical company’s stock worth $9,287,000 after purchasing an additional 1,680 shares during the last quarter. AXA increased its position in Jazz Pharmaceuticals by 23.2% in the third quarter. AXA now owns 116,862 shares of the specialty pharmaceutical company’s stock worth $17,091,000 after purchasing an additional 22,007 shares during the last quarter. Neuberger Berman Group LLC increased its position in Jazz Pharmaceuticals by 26.6% in the third quarter. Neuberger Berman Group LLC now owns 117,345 shares of the specialty pharmaceutical company’s stock worth $17,162,000 after purchasing an additional 24,626 shares during the last quarter. California Public Employees Retirement System increased its position in Jazz Pharmaceuticals by 4.8% in the third quarter. California Public Employees Retirement System now owns 122,201 shares of the specialty pharmaceutical company’s stock worth $17,872,000 after purchasing an additional 5,601 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in Jazz Pharmaceuticals in the third quarter worth $291,000. Institutional investors own 90.73% of the company’s stock.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
